FABIANI, IACOPO
 Distribuzione geografica
Continente #
NA - Nord America 2.032
EU - Europa 1.834
AS - Asia 1.773
SA - Sud America 513
AF - Africa 44
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.202
Nazione #
US - Stati Uniti d'America 1.921
SG - Singapore 806
RU - Federazione Russa 670
IT - Italia 597
CN - Cina 436
BR - Brasile 423
VN - Vietnam 208
DE - Germania 107
GB - Regno Unito 98
NL - Olanda 83
CA - Canada 72
HK - Hong Kong 67
FI - Finlandia 60
TR - Turchia 51
FR - Francia 49
IN - India 41
BD - Bangladesh 39
IE - Irlanda 37
PL - Polonia 37
AR - Argentina 30
MX - Messico 29
ES - Italia 22
ID - Indonesia 22
ZA - Sudafrica 22
EC - Ecuador 21
IQ - Iraq 19
JP - Giappone 16
SE - Svezia 16
PK - Pakistan 14
AT - Austria 13
IL - Israele 13
UA - Ucraina 11
LT - Lituania 10
CO - Colombia 9
PE - Perù 8
SA - Arabia Saudita 8
VE - Venezuela 8
BE - Belgio 7
PY - Paraguay 7
AE - Emirati Arabi Uniti 6
MA - Marocco 5
UZ - Uzbekistan 5
EG - Egitto 4
KE - Kenya 4
RO - Romania 4
AU - Australia 3
DO - Repubblica Dominicana 3
KR - Corea 3
KZ - Kazakistan 3
LB - Libano 3
MG - Madagascar 3
MY - Malesia 3
TT - Trinidad e Tobago 3
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CL - Cile 2
CZ - Repubblica Ceca 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CR - Costa Rica 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
DZ - Algeria 1
GD - Grenada 1
GT - Guatemala 1
HR - Croazia 1
JO - Giordania 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
NP - Nepal 1
PG - Papua Nuova Guinea 1
PH - Filippine 1
PS - Palestinian Territory 1
SI - Slovenia 1
SR - Suriname 1
TH - Thailandia 1
TN - Tunisia 1
TV - Tuvalu 1
Totale 6.202
Città #
Dallas 805
Singapore 440
Ashburn 211
Beijing 193
Moscow 135
Los Angeles 81
Ho Chi Minh City 79
Hong Kong 65
Milan 57
São Paulo 54
Munich 50
New York 47
The Dalles 45
Hefei 41
Rome 41
Boardman 39
Dublin 37
Hanoi 36
Istanbul 34
Warsaw 33
Florence 32
Pisa 31
Santa Clara 30
Lappeenranta 27
London 25
Beauharnois 23
Montreal 23
Naples 22
Brooklyn 21
Council Bluffs 21
Helsinki 21
Houston 21
Denver 20
Orem 20
Buffalo 19
Lucca 19
Rio de Janeiro 19
Genoa 18
Nuremberg 18
Johannesburg 17
Phoenix 17
Chicago 16
Frankfurt am Main 16
Chennai 15
Mexico City 15
Stockholm 15
Tokyo 15
Haiphong 14
Poplar 14
Atlanta 13
Boston 13
Seattle 13
Mumbai 12
Manchester 11
Amsterdam 10
Assago 10
Curitiba 10
Toronto 10
Belo Horizonte 9
Brescia 9
Paris 9
San Francisco 9
Tel Aviv 9
Turin 9
Turku 9
Cascina 8
Porto Alegre 8
Quito 8
Washington 8
Ankara 7
Biên Hòa 7
Bologna 7
Brussels 7
Charlotte 7
Goiânia 7
Guayaquil 7
Hải Dương 7
Livorno 7
Palermo 7
Brasília 6
Da Nang 6
Guangzhou 6
Phủ Lý 6
Redondo Beach 6
Santa Croce sull'Arno 6
Shanghai 6
Dhaka 5
Pittsburgh 5
Salt Lake City 5
Secaucus 5
Tashkent 5
Thái Nguyên 5
Vienna 5
Bad Vilbel 4
Bauru 4
Bexley 4
Bắc Giang 4
Casablanca 4
Caxias do Sul 4
Dongguan 4
Totale 3.479
Nome #
Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation 453
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 328
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 206
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 205
Atrial amyloidosis: mechanisms and clinical manifestations 204
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 189
Role of Imaging in Cardiomyopathies 181
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 177
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 174
Valvular heart disease in patients with cardiac amyloidosis 171
Disease features and management of cardiomyopathies in women 171
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 167
Sex-specific associations of myocardial perfusion imaging with outcomes in patients with suspected chronic coronary syndrome 166
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 165
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 155
Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook 155
Valve disease in cardiac amyloidosis: an echocardiographic score 153
Cardiovascular toxicity from therapies for light chain amyloidosis 150
Assessing cardiac mechanics through left ventricular haemodynamic forces 149
Use of new and emerging cancer drugs: what the cardiologist needs to know 148
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 145
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 139
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 135
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 130
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 130
Magnetic resonance imaging for diagnostic workup of embolic stroke of undetermined source: A systematic review 127
Treatment Options in AF Patients with Cancer; Focus on Catheter Ablation 127
Galectin-3 and Risk for Cancer or Heart Failure: Does Sex Matter? 127
Critical Reading of cardiovascular trials with neutral or negative results 115
Exercise oscillatory ventilation in heart failure and brain–lung–heart–muscle crosstalk 114
Advancing Cardiovascular Risk Stratification and Functional Assessment: A Narrative Review of CPET and ESE Applications 113
Echocardiographic Estimate of Pulmonary Capillary Wedge Pressure Improves Outcome Prediction in Heart Failure Patients with Reduced and Mildly Reduced Ejection Fraction 112
Partial Lipodystrophy and LMNA p.R545H Variant 106
More cardiopulmonary effort testing needed in HFpEF! 105
Ischemic Heart Disease in Liver Transplant Candidates With High Bleeding Risk: Any Way Out? 102
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 100
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 100
Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation 96
Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study 93
Response to ‘Is the left atrium the key in the amyloid imaging lock?’ 78
Safety and Effectiveness of Sodium-Glucose Co-Transporter 2 Inhibitors in Active Cancer Patients with Heart Failure: Results of the Observational TOSCA Trial 61
null 29
Totale 6.251
Categoria #
all - tutte 29.059
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.059


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202347 0 0 0 0 4 5 4 6 18 5 5 0
2023/2024246 1 0 48 34 10 22 30 8 6 16 14 57
2024/20252.115 40 48 85 51 121 122 291 414 200 149 276 318
2025/20263.843 379 726 859 941 619 319 0 0 0 0 0 0
Totale 6.251